drugset / Trial / NCT04493255

A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants

NCT04493255

Phase 1 Completed 8 enrolled Eisai Inc.
NaSingle-groupOpen-labelOther

Summary

The primary objective of this study is to determine the pharmacokinetics (PK) and excretion of E7090 and its metabolites in healthy male participants. Also, to assess the safety and tolerability of a single dose of E7090 in healthy male participants.

Timeline

Start
2020-09-09
Primary completion
2020-10-21
Completion
2020-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject E7090 Small molecule 35 mg Oral

Indications

No indication recorded.